Skip to main content

Table 1 Comparisons of clinical and imaging characteristics of patients

From: Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis

Characteristic

Before PSM

After PSM

Chemotherapy + IRE

Chemotherapy + radiotherapy

Total number

P value

Chemotherapy + IRE

Chemotherapy + radiotherapy

Total number

P value

Total number

 

36

40

76

 

36

36

72

 

Age (years)

≤60

20

24

44

0.817

20

20

40

1.000

> 60

16

16

32

16

16

32

Gender

Female

19

15

34

0.248

19

15

34

0.479

Male

17

25

42

17

21

38

Tumor size (cm)

≤2

1

2

3

0.623

1

2

3

0.790

2~4

20

18

38

20

18

38

>4

15

20

35

15

16

31

Tumor grade

Well

3

5

8

0.763

3

5

8

0.633

Moderate

20

23

43

20

21

41

Poor

13

12

25

13

10

23

LN metastasis

Absent

9

14

23

0.454

9

14

23

0.312

Present

27

26

53

27

22

49

Tumor site

Head

18

18

36

0.498

18

16

34

0.562

Body

15

15

30

15

14

29

Tail

3

7

10

3

6

9

TNM stage

IIB

4

9

13

0.232

4

8

12

0.343

III

32

31

63

32

28

60

WBC (*109)

≤10

32

37

69

0.702

32

33

65

0.989

> 10

4

3

7

4

3

7

HGB (g/L)

≤120

1

7

8

0.059

1

6

7

0.107

>120

35

33

68

35

30

65

PLT (*109)

≤300

31

34

65

0.978

31

31

62

1.000

>300

5

6

11

5

5

10

ALT (U/L)

≤40

26

31

57

0.608

26

28

54

0.786

> 40

10

9

19

10

8

18

AST (U/L)

≤40

29

34

63

0.762

29

31

60

0.753

>40

7

6

13

7

5

12

ALP (U/L)

≤100

19

28

47

0.158

19

25

44

0.227

>100

17

12

29

17

11

28

GGT (U/L)

≤45

19

22

41

0.935

19

20

39

1.000

>45

17

18

35

17

16

33

ALB (g/L)

≤40

4

4

8

0.957

4

4

8

1.000

>40

32

36

68

32

32

64

TBIL (umol/L)

≤20.5

27

33

60

0.574

27

30

57

0.563

>20.5

9

7

16

9

6

15

IBIL (umol/L)

≤15

32

39

71

0.184

32

35

67

0.357

>15

4

1

5

4

1

5

CRP (ng/L)

≤3

24

24

48

0.637

24

21

45

0.627

>3

12

16

28

12

15

27

CEA (ng/mL)

≤5

21

25

46

0.815

21

22

43

0.982

>5

15

15

30

15

14

29

CA19–9 (U/ml)

≤35

9

9

18

0.962

9

8

17

0.987

>35

27

31

58

27

28

55

Chemotherapy

FOLFIRINOX

21

18

39

0.262

21

17

38

0.479

Gem

15

22

37

15

19

34

  1. IRE irreversible electroporation, LN lymph node metastasis, TNM tumor-node-metastasis stage, WBC white blood cell count, PLT platelet count, ALT alanine transaminase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT glutamyl transpeptidase, ALB albumin, TBIL total bilirubin, IBIL indirect bilirubin, CRP C-reactive protein, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us